All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel
.
Note this is an amended filing that contain additional holdings that were omitted from a previous filing. This is not likely to be
an accurate picture of the total holdings of this firm.
Security |
Imputed Share Price |
Prev Shares |
Current Shares |
Change (Percent) |
Prev Value (USD x1000) |
Current Value (USD x1000) |
Change (Percent) |
RNAC / Cartesian Therapeutics, Inc.
|
|
|
|
|
|
|
|
SRPT / Sarepta Therapeutics, Inc.
|
|
|
|
|
|
|
|
SRPT / Sarepta Therapeutics, Inc. Call
|
|
|
|
|
|
|
|
SLN / Silence Therapeutics plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
NMRA / Neumora Therapeutics, Inc.
|
|
|
|
|
|
|
|
BOLD / Boundless Bio, Inc.
|
|
|
|
|
|
|
|
NXTC / NextCure, Inc.
|
|
|
|
|
|
|
|
ENGN / enGene Holdings Inc.
|
|
|
|
|
|
|
|
RCKT / Rocket Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
ARGX / argenx SE - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
LCTX / Lineage Cell Therapeutics, Inc.
|
|
|
|
|
|
|
|
STOK / Stoke Therapeutics, Inc.
|
|
|
|
|
|
|
|
SYRE / Spyre Therapeutics, Inc.
|
|
|
|
|
|
|
|
FULC / Fulcrum Therapeutics, Inc. Call
|
|
|
|
|
|
|
|
RAPP / Rapport Therapeutics, Inc.
|
|
|
|
|
|
|
|
NUVL / Nuvalent, Inc.
|
|
|
|
|
|
|
|
UNCY / Unicycive Therapeutics, Inc.
|
|
|
|
|
|
|
|
ELVN / Enliven Therapeutics, Inc.
|
|
|
|
|
|
|
|
JANX / Janux Therapeutics, Inc.
|
|
|
|
|
|
|
|
GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) Call
|
|
|
|
|
|
|
|
ERAS / Erasca, Inc.
|
|
|
|
|
|
|
|
TRVI / Trevi Therapeutics, Inc.
|
|
|
|
|
|
|
|
DSGN / Design Therapeutics, Inc.
|
|
|
|
|
|
|
|
XENE / Xenon Pharmaceuticals Inc.
|
|
|
|
|
|
|
|
VERA / Vera Therapeutics, Inc.
|
|
|
|
|
|
|
|
CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
ADVM / Adverum Biotechnologies, Inc.
|
|
|
|
|
|
|
|
AVTX / Avalo Therapeutics, Inc.
|
|
|
|
|
|
|
|
SKYE / Skye Bioscience, Inc.
|
|
|
|
|
|
|
|
ATYR / aTyr Pharma, Inc.
|
|
|
|
|
|
|
|
IOBT / IO Biotech, Inc.
|
|
|
|
|
|
|
|
ALLK / Allakos Inc.
|
|
|
|
|
|
|
|
RLAY / Relay Therapeutics, Inc.
|
|
|
|
|
|
|
|
BHVN / Biohaven Ltd.
|
|
|
|
|
|
|
|
APLS / Apellis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
APLT / Applied Therapeutics, Inc.
|
|
|
|
|
|
|
|
MLTX / MoonLake Immunotherapeutics
|
|
|
|
|
|
|
|
NUVB.WS / Panacea Acquisition Corp. - Equity Warrant
|
|
|
|
|
|
|
|
MRUS / Merus N.V.
|
|
|
|
|
|
|
|
CYBN / Cybin Inc.
|
|
|
|
|
|
|
|
RVMD / Revolution Medicines, Inc.
|
|
|
|
|
|
|
|
ANNX / Annexon, Inc. Call
|
|
|
|
|
|
|
|
IONS / Ionis Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
XBI / SPDR Series Trust - SPDR S&P Biotech ETF Put
|
|
|
|
|
|
|
|
ELEV / Elevation Oncology, Inc.
|
|
|
|
|
|
|
|
XNCR / Xencor, Inc.
|
|
|
|
|
|
|
|
GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
ANNX / Annexon, Inc.
|
|
|
|
|
|
|
|
IDYA / IDEAYA Biosciences, Inc.
|
|
|
|
|
|
|
|
IMVT / Immunovant, Inc.
|
|
|
|
|
|
|
|
IRON / Disc Medicine, Inc.
|
|
|
|
|
|
|
|
ATXS / Astria Therapeutics, Inc.
|
|
|
|
|
|
|
|
AKRO / Akero Therapeutics, Inc.
|
|
|
|
|
|
|
|
OCUL / Ocular Therapeutix, Inc.
|
|
|
|
|
|
|
|
DYN / Dyne Therapeutics, Inc.
|
|
|
|
|
|
|
|
APLS / Apellis Pharmaceuticals, Inc. Call
|
|
|
|
|
|
|
|
OLMA / Olema Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|